key: cord-0759395-4ua67ztd
authors: Lam, L. M.; Murphy, S. J.; Kuri-Cervantes, L.; Weisman, A. R.; Ittner, C. A. G.; Reilly, J. P.; Pampena, M. B.; Betts, M. R.; Wherry, E. J.; Song, W.-C.; Lambris, J. D.; Cines, D. B.; Meyer, N. J.; Mangalmurti, N. S.
title: Erythrocytes Reveal Complement Activation in Patients with COVID-19
date: 2020-05-22
journal: medRxiv : the preprint server for health sciences
DOI: 10.1101/2020.05.20.20104398
sha: 99a9b1b18f38bd74b49d7f1773381a64f6e77449
doc_id: 759395
cord_uid: 4ua67ztd

COVID-19, the disease caused by the SARS-CoV-2 virus, can progress to multi-organ failure characterized by respiratory insufficiency, arrhythmias, thromboembolic complications and shock. The mortality of patients hospitalized with COVID-19 is unacceptably high and new strategies are urgently needed to rapidly identify and treat patients at risk for organ failure. Clinical epidemiologic studies demonstrate that vulnerability to organ failure is greatest after viral clearance from the upper airway, which suggests that dysregulation of the host immune response is a critical mediator of clinical deterioration and death. Autopsy and pre-clinical evidence implicate aberrant complement activation in endothelial injury and organ failure. A potential therapeutic strategy warranting investigation is to inhibit complement, with case reports of successful treatment of COVID-19 with inhibitors of complement. However, this approach requires careful balance between the host protective and potential injurious effects of complement activation, and biomarkers to identify the optimal timing and candidates for therapy are lacking. Here we report the presence of complement activation products on circulating erythrocytes from hospitalized COVID-19 patients using flow cytometry. These findings suggest that novel erythrocyte-based diagnostics provide a method to identify patients with dysregulated complement activation.

An ancient arm of innate immunity, the complement system provides a front-line of defense against invading micro-organisms. This multi-tiered and highly coordinated system is vital for the innate immune response to pathogens, removal of dead cells and maintenance of homeostasis. Initially described as a complement to antibody mediated immunity, it was later discovered that the complement system is evolutionarily older than antibody-mediated immunity and its activation can be initiated by lectins and by a C3 tick-over mechanism. Thus, the three pathways of complement activation can be engaged by distinct initiators including antigenantibody complexes (classical pathway), lectins (lectin pathway) and spontaneous C3 hydrolysis (alternative pathway). Although the complement system promotes clearance of pathogens through opsonization, inflammation and cytolysis, dysregulated complement activation can lead to cellular injury, microvascular thrombosis and organ failure 14 . The latter point is highlighted by several well-characterized human diseases including paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) that result from complement dysregulation 15, 16 . Animal models with complement regulator deficiencies or mutations have also demonstrated development of tissue injury, coagulopathy and thrombotic microangiopathy caused by insufficient complement regulation 17 .

Complement-containing immune complexes bind to cells through a number of specific receptors, including complement receptor 1 (CR1), which recognizes complement activation products C3b and iC3b 18 . Human CR1 is abundantly expressed on the surface of the nearly thirty trillion erythrocytes (red blood cells, RBCs) in circulation. Immune adherence, binding of antigen-antibody-complement complex to RBCs, was first described in the 1950s and is one example of how erythrocytes modulate innate responses 19-21 . We hypothesized that complement

To detect complement activation in patients with COVID-19, we measured erythrocytebound C3b, iC3b, C3dg and C4d using flow cytometry (see online methods). RBCs were obtained from healthy donors (HD) or patients with COVID-19 (Table 1 , online methods) on day 0 and day 7 of study enrollment. The percentage of RBCs with bound C3b/iC3b/C3dg was markedly elevated in hospitalized COVID-19 patients admitted to the ICU when compared with HD and increased even further by day 7 (Figure 1 a&b) . C4d was also increased on RBCs from COVID patients when compared with healthy donors (Supplemental Figure 1 ).

Immunofluorescence staining demonstrated that COVID-19 erythrocytes not only bound C3 fragments, but also bound viral spike protein, suggesting activation of the classic pathway of complement and immune complex deposition on the RBCs (Fig 2) . Together, these data suggest that complement activation products and viral antigen are present on RBCs in patients with COVID-19.

We next examined the association of RBC-bound complement, C-reactive protein (CRP), d-dimer and clinical outcomes (patient details are in Table 1 ). We detected a moderate inverse correlation (rho -0.55) between the percentage of C3 bearing RBCs at the early timepoint and the clinically measured high sensitivity CRP (p=0.05), measured in 13/35 subjects, but not with the duration of symptoms before blood draw, d-dimer level, absolute lymphocyte count, ferritin level, or maximum oxygenation required. The median C3 percentage was not different between subjects who developed ARDS or not, though observations are limited and inconclusive given the small cohort of patients studied.

The presence of C4 and C3 on patient RBCs suggests activation of the classical pathway of complement. Direct binding of the N protein of SARS-CoV-1 or SARS-CoV-2 to MASP-2 All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.20.20104398 doi: medRxiv preprint (Mannan-binding lectin serine protease 2) may also lead to activation of the lectin pathway as well 10 . Polymorphisms in the MBL protein, which initiates the lectin pathway, and mutations or dysfunction of complement regulatory proteins are implicated in a diverse group of disorders characterized by intravascular thrombosis [15] [16] [17] [22] [23] [24] . Furthermore, risk factors for COVIDassociated lung injury such as diabetes have been associated with high circulating levels of MBL and dysfunctional complement regulatory proteins on the endothelium and erythrocytes [25] [26] [27] [28] [29] .

Although the small sample size did not permit us to draw associations between RBCbound complement and clinical outcomes, several clinically relevant implications arise from our findings. First, our findings suggest support a potential role for complement in the pathophysiology of COVID-19. Second, because plasma-based assays of individual complement components or total complement activity may fail to reflect the levels of complement activation on cell surfaces that is responsible for tissue injury 30 Interfering with complement activation requires the need to balance the protective and potentially injurious effects of these proteins on the host. The evolutionarily ancient origins of this system coupled with its importance in host defense against highly virulent bat-borne viruses including Nipah Virus, MERS-CoV and SARS-CoV-1 and 2 suggest that complement activation represents an atavistic response of the host 10,31-33 . Moreover, immune adherence, the binding of complement-containing immune complex to erythrocytes, may provide a mechanism to immobilize and transport pathogens to immune cells 21 . On the other hand, deposition of immune All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.20.20104398 doi: medRxiv preprint complexes and complement on RBCs may alter their rheology and thereby promote intravascular stasis and thrombosis that contribute to the pathogenesis of virus associated lung injury 10,32,34-38 .

Additional studies will be needed to determine if and when binding of complement and viral antigen to erythrocytes contributes directly to organ injury during COVID-19 infection.

In sum, our findings suggest that RBC-immune adherence occurs in COVID-19 and flow cytometric analysis of RBCs provides a clinically feasible means to help identify patients who are susceptible to complement-mediated host injury and might therefore benefit from intervention with complement inhibitors. The role of RBC immune adherence in delivery of viral antigen to immune cells has yet to be elucidated. However, exploiting this innate immune mechanism to detect pathologic complement activation may hold one key to preventing organ injury in infectious and autoimmune systemic disorders characterized by complement dysregulation.

All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. in accordance with protocols approved by the regional ethical research boards and the Declaration of Helsinki, was given by subjects or their proxies. Samples were processed within three hours of collection. Whole blood was centrifuged for 15 minutes at 3,000 rpm and plasma was removed.

Red blood cell isolation. Whole blood was obtained from healthy donors in EDTA tubes (BD Bioscience). Blood from healthy donors and COVID-19 patients was centrifuged for 5 minutes at 800 g and remaining plasma and buffy coat were removed. Red blood cells (RBCs) from pellet were then diluted in PBS for flow cytometry (1 uL RBCs / 1 mL PBS), confocal microscopy (1 uL RBCs / 1 mL PBS), and quantitative PCR (5 uL RBCs in 100 uL PBS). All work was done in the biosafety cabinet under enhanced-BSL2 conditions. Flow cytometry. Diluted RBCs (100uL) were incubated with anti-complement C3/C3b/iC3b/C3d (BioLegend, 1 ug/mL), anti-C4d (Immunoquest, 1 ug/mL), anti-IgM (BioLegend, 5 uL), or IgG2a, K isotype (BioLegend, 1ug/mL) antibody for 45 minutes followed by two washes in PBS. Cells were then resuspended in 100 uL of PE Goat anti-mouse IgG All rights reserved. No reuse allowed without permission.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted May 22, 2020. . https://doi.org/10.1101/2020.05.20.20104398 doi: medRxiv preprint

Covid-19: risk factors for severe disease and death

Critical Care Utilization for the COVID-19

Early Experience and Forecast During an Emergency Response

Pulmonary and Cardiac Pathology in Covid-19: The First Autopsy Series from New Orleans. medRxiv

Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study

Covid-19 in Critically Ill Patients in the Seattle Region -Case Series

Viral dynamics in mild and severe cases of COVID-19

Relationship between the ABO Blood Group and the COVID-19

Virological assessment of SARS-CoV-2

Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation. medRxiv

Complement as a target in COVID-19?

Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101

Complement: a key system for immune surveillance and homeostasis

Atypical hemolytic-uremic syndrome

Paroxysmal nocturnal hemoglobinuria

Murine systemic thrombophilia and hemolytic uremic syndrome from a factor H point mutation

The Evolving Erythrocyte: Red Blood Cells as Modulators of Innate Immunity

A receptor for the malarial parasite Plasmodium vivax: the erythrocyte chemokine receptor

The immune-adherence phenomenon; an immunologically specific reaction between microorganisms and erythrocytes leading to enhanced phagocytosis

Complement Factor H Mutation <em>W1206R</em> Causes Retinal Thrombosis and Ischemic Retinopathy in Mice

Differential contribution of C5aR and C5b-9 pathways to renal thrombic microangiopathy and macrovascular thrombosis in mice carrying an atypical hemolytic syndrome-related factor H mutation

Clinical promise of next-generation complement therapeutics

Glycation of the complement regulatory protein CD59 is a novel biomarker for glucose handling in humans

Glycation of CD59 impairs complement regulation on erythrocytes from diabetic subjects

The effect of glycation of CD59 on complement-mediated cytolysis

Distinct Longitudinal Associations of MBL, MASP-1, MASP-2, MASP-3, and MAp44 With Endothelial Dysfunction and Intima-Media Thickness: The Cohort on Diabetes and Atherosclerosis Maastricht (CODAM) Study

Current and Future Approaches for Monitoring Responses to Anticomplement Therapeutics

A novel factor I activity in Nipah virus inhibits human complement pathways through cleavage of C3b

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis

Blockade of the C5a-C5aR axis alleviates lung damage in hDPP4-transgenic mice infected with MERS-CoV

Inhibition of complement activation alleviates acute lung injury induced by highly pathogenic avian influenza H5N1 virus infection

Treatment with anti-C5a antibody improves the outcome of H7N9 virus infection in African green monkeys

Complement C5 activation during influenza A infection in mice contributes to neutrophil recruitment and lung injury

Severe COVID-19 infection and thrombotic microangiopathy: success doesn't come easily

Role of red blood cells in haemostasis and thrombosis

No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity